Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPRA | P18433 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPRE | P23469 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22164333 | 0.84 | PTGDR2 (0.49) | PTGDR2PKMTDP1HTTAKR1B1 | |
| SCHEMBL20522189 | 0.83 | TSHR (0.56) | KDM4ETSHRPOLBL3MBTL1PTPRC | |
| SCHEMBL5833932 | 0.82 | TDP1 (0.50) | PTGDR2PKMTDP1MAPTTSHR | |
| SCHEMBL8528987 | 0.81 | PTGDR2 (0.55) | PTGDR2PKMTDP1MAPTTSHR | |
| SCHEMBL3044855 | 0.81 | PTGDR2 (0.79) | PTGDR2PKMTDP1KDM4EAKR1B1 | |
| SCHEMBL8478888 | 0.80 | PTPN11 (0.51) | MAPTKDM4ETSHRPTPN1PTPN6 | |
| SCHEMBL4138843 | 0.79 | PKM (0.71) | PTGDR2PKMTDP1KDM4EHTT | |
| SCHEMBL4143335 | 0.79 | TDP1 (0.70) | PTGDR2TDP1MAPTKDM4ETSHR | |
| SCHEMBL16742721 | 0.79 | TDP1 (0.70) | PTGDR2PKMTDP1MAPTAKR1B1 | |
| SCHEMBL13616955 | 0.79 | PTGDR2 (0.54) | PTGDR2PKMTDP1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | NAGASAKI UNIVERSITY (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2113258-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | Nagasaki University (JP) | 2009-11-04 | — | — | EP | disclosed |
| EP-2113258-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | Nagasaki University (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7405299-B2 | Compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1567527-A1 | CONDENSED PYRAZOLO DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050659-A1 | NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058295-A1 | Novel compounds as pharmaceutical agents | TGFB1, TGFB2, TGFBR1 | PTGDR2 1078/4885PKM 1983/4885TDP1 3300/4885 |
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | APP, APBA1, BACE1 | PTGDR2 4234/4885PKM 3908/4885TDP1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.